Myos Corp (MYOS) 14.75 $MYOS
MYOS elects Douglas Weekes as chief commercial officer
M2 - Thu Jul 31, 5:49AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) reported on Wednesday that Douglas Weekes has been named as its chief commercial officer.
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
Marketwire - Wed Jul 30, 7:04AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed Douglas Weekes as Chief Commercial Officer. Mr. Weekes will lead the Company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin(TM). Positive clinical results have demonstrated that daily use of Fortetropin along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reduced inflammation. Mr. Weekes will lead the creation of several bionutrition products including bars, meal replacement formats and ready to drink beverages utilizing Fortetropin.
MYOS renews manufacturing and supply agreement of Fortetropin with DIL
M2 - Mon Jul 28, 6:19AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) said on Friday that it has extended its agreement for the continued manufacturing and supply of the first clinically proven natural myostatin inhibitor Fortetropin with Deutsches Institut fuer Lebensmitteltechnik e.V (DIL), the German Institute for Food Technologies.
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
Marketwire - Fri Jul 25, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL" , the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin(TM), the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
GlobeNewswire - Thu Jul 24, 7:41AM CDT
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 -
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects
Marketwire - Tue Jul 22, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin(TM) (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa.
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
Marketwire - Thu Jul 17, 6:05AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.
MYOS hires Dr. J. Craig Venter to board
M2 - Tue Jul 15, 5:06AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) revealed on Monday the addition of genomic pioneer, Dr. J. Craig Venter, Ph.D. to its board of directors.
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Marketwire - Mon Jul 14, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors.
MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
Marketwire - Wed Jul 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has received approval for the listing of its common stock on the NASDAQ Capital Market ("NASDAQ" . The common stock is expected to begin trading on the NASDAQ at market open on July 10, 2014 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9, 2014.
MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
Marketwire - Thu Jun 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview ("Worldview" .
MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
Marketwire - Tue Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA" with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations.
MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
Marketwire - Tue Apr 01, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS)
MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
Marketwire - Thu Mar 27, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that it will participate in a working group on March 28, 2014 including physicians, researchers, patient groups and the U.S. Food and Drug Administration (FDA) to develop measures of clinical benefit for therapeutic products developed or used to treat sarcopenia. The group, the Aging in Motion (AIM) Coalition, was formed to promote understanding about the importance of improving research efforts and developing innovative treatments in the area of sarcopenia and age-related functional decline. At present, the FDA does not have a policy on sarcopenia and currently there are no drugs approved for this disease indication.
MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
Marketwire - Mon Mar 17, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that the Company will participate in the New Jersey MDA Muscle Walk fundraising event on March 23, 2014 at the Prudential Center in Newark, NJ.
MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
Marketwire - Wed Mar 12, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company" , announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014.
MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
MYOS elects Douglas Weekes as chief commercial officer
M2 - Thu Jul 31, 5:49AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) reported on Wednesday that Douglas Weekes has been named as its chief commercial officer.
MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer
Marketwire - Wed Jul 30, 7:04AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed Douglas Weekes as Chief Commercial Officer. Mr. Weekes will lead the Company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin(TM). Positive clinical results have demonstrated that daily use of Fortetropin along with exercise may be beneficial to improving lean muscle mass, which has significant therapeutic effects for overall health including bone density, control of serum glucose, triglyceride levels and reduced inflammation. Mr. Weekes will lead the creation of several bionutrition products including bars, meal replacement formats and ready to drink beverages utilizing Fortetropin. MYOS renews manufacturing and supply agreement of Fortetropin with DIL
M2 - Mon Jul 28, 6:19AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) said on Friday that it has extended its agreement for the continued manufacturing and supply of the first clinically proven natural myostatin inhibitor Fortetropin with Deutsches Institut fuer Lebensmitteltechnik e.V (DIL), the German Institute for Food Technologies.
MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin
Marketwire - Fri Jul 25, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V ("DIL" , the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin(TM), the first clinically proven natural myostatin inhibitor. DIL is a world leader in developing and providing the finest products in food technology today. Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin
GlobeNewswire - Thu Jul 24, 7:41AM CDT
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 -
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects
Marketwire - Tue Jul 22, 7:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today positive top-line results of its clinical trial designed to study the effects of Fortetropin(TM) (MYO-T12®) in conjunction with modest resistance training in male subjects led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa. MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia
Marketwire - Thu Jul 17, 6:05AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market. MYOS hires Dr. J. Craig Venter to board
M2 - Tue Jul 15, 5:06AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) revealed on Monday the addition of genomic pioneer, Dr. J. Craig Venter, Ph.D. to its board of directors.
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Marketwire - Mon Jul 14, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors. MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market
Marketwire - Wed Jul 09, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has received approval for the listing of its common stock on the NASDAQ Capital Market ("NASDAQ" . The common stock is expected to begin trading on the NASDAQ at market open on July 10, 2014 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9, 2014. MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview
Marketwire - Thu Jun 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview ("Worldview" . MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science
Marketwire - Tue Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA" with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations. MYOS' net loss from operations widens to USD4.267m in 2013
M2 - Wed Apr 02, 4:58AM CDT
Biotherapeutics company MYOS (OTCBB:MYOS)on Tuesday declared a net loss from operations of approximately USD4.267m for the full year ended 31 December 2013.
MYOS Corporation Reports 2013 Fourth Quarter and Full Year Results
Marketwire - Tue Apr 01, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS)
MYOS Corporation Joins Scientific Working Group Aging in Motion to Develop Patient Centered Treatment Measures for Sarcopenia
Marketwire - Thu Mar 27, 6:35AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that it will participate in a working group on March 28, 2014 including physicians, researchers, patient groups and the U.S. Food and Drug Administration (FDA) to develop measures of clinical benefit for therapeutic products developed or used to treat sarcopenia. The group, the Aging in Motion (AIM) Coalition, was formed to promote understanding about the importance of improving research efforts and developing innovative treatments in the area of sarcopenia and age-related functional decline. At present, the FDA does not have a policy on sarcopenia and currently there are no drugs approved for this disease indication. MYOS Corporation Takes Steps to Make a Difference in the Fight Against Muscle Disease at the New Jersey MDA Muscle Walk
Marketwire - Mon Mar 17, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that the Company will participate in the New Jersey MDA Muscle Walk fundraising event on March 23, 2014 at the Prudential Center in Newark, NJ. MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12(R) at the International Conference on Frailty and Sarcopenia Research
Marketwire - Wed Mar 12, 7:05AM CDT
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"
, announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014. MYOS Corporation Initiates Clinical Study of MYO-T12(R) in Adult Women
Marketwire - Thu Feb 27, 7:05AM CST
MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, today announced the initiation of its first clinical study of MYO-T12(R) in women. The study, led by Stacy Zamuido, Ph.D., Senior Scientist and Director of Research for the Department of Obstetrics and Gynecology at Hackensack University Medical Center, will determine the effect of MYO-T12(R) on blood chemistry in healthy adult females. The 20-patient clinical trial will also observe the effect of MYO-T12(R) on body mass index (BMI) and waist circumference in addition to other indices of muscle health.
